BioCentury | Apr 13, 2021
Product Development

FDA requests more data from Provention; plus Iterum, Seagen-Genmab, Pfizer and Gilead

...with disease progression on or after chemotherapy. The PDUFA date for the antibody-drug conjugate targeting TF...
...Tissue factorJAK-1 - Janus kinase-1TROP2 (TACSTD2) (EGP-1)- Tumor-associated calcium signal transducer 2 BC Staff Sulopenem etzadroxil-probenecid (PF-03709270) HuMax-TF-ADC...
...tofacitinib extended release Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) Iterum Therapeutics plc Seagen Inc. Genmab A/S Pfizer Inc. Gilead Sciences Inc. Tissue factor (TF...
BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

...series B financing led by Lilly Asia Ventures with participation from Loyal Valley Capital, Lanting Capital, TF...
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...with Arch Venture Partners; they were joined by Boyu Capital, General Atlantic, Sequoia Capital China, TF...
...$100 millionInvestors: Lilly Asia Ventures Fund, Arch Venture Partners,  Boyu General Atlantic, Sequoia Capital China, TF...
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

...in-license XB002 (formerly ICON-2) from Iconic Therapeutics Inc. for a $20 million option fee. The TF-targeting...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...RMB800 million ($121.6 million) in a pre-IPO round co-led by Yunfeng Capital, Yingke PE and TF...
BioCentury | Aug 15, 2020
Finance

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

...SRL; Maplebrook Ltd.; Full Moon Resources Ltd.; Viktor Pan; Zheng Zhou; Yunfeng Fund III L.P.; TF...
BioCentury | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

...a series C round to advance its cancer pipeline. The round was co-led by Tigermed, TF...
BioCentury | Nov 14, 2019
Company News

Nov. 13 Company Quick Takes: FDA panel rebuffs Jardiance; plus Nucala, Cellular Biomedicine, BeiGene, Autolus and Noile-Immune

...syndicate led by CEO Bizuo “Tony” Liu, other undisclosed company executives, Hillhouse Bio Holdings and TF...
BioCentury | Aug 23, 2019
Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

...an upfront payment and equity investment. Financial terms were undisclosed. Iconic is developing ICON-4, an anti-TF...
...Btk - Burton's tyrosine kinase; GCGR - Glucagon receptor; GLP-1R (GLP1R) - Glucagon-like peptide-1 receptor; TF...
BioCentury | Jul 19, 2019
Financial News

Genmab’s plans after $500M NASDAQ debut

...listing on NASDAQ Thursday to fuel clinical development and commercialization of antibody-drug conjugate tisotumab vedotin (HuMax-TF-ADC...
...File for IPOs" ). Hongjiang Li, Staff Writer HuMax-TF-ADC, tisotumab vedotin Fulcrum Therapeutics Inc. Genmab A/S Mirum Pharmaceuticals Inc. Tissue factor (TF...
Items per page:
1 - 10 of 256